DDX41 and systemic lupus erythematosus: Notable observations from phase III Belimumab trials BLISS−52 and BLISS−76 (30, 31) were that increased anti-DNA Ab titers predicted lupus flares (6, 7), while successful treatment resulted in reduced anti-DNA Abs (29), positively correlating anti-DNA Abs with disease manifestations.